Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC Pipeline Landscape and Therapeutics Market Review for H1 2017

Published on : Jul 06, 2017

Albany, New York, July 6, 2017: The latest pipeline review has been done by research experts which encapsulate vital information on the Serine Protein Kinase ATM targeted therapeutics with well-updated data in H1 2017. This analysis has been added to the market intelligence repository of Market Research Hub (MRH), with the title of “Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC - Pipeline Review, H1 2017”. The guide also covers the descriptive pharmacological action of the therapeutics on the basis of complete research & development history, latest news and press releases from company/ university sites.

Initially, the report provides a snapshot of the global therapeutic landscape of Serine protein Kinase ATM (Ataxia Telangiectasia Mutated) with its overview, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It has been analyzed that the protein kinase ataxia-telangiectasia mutated (ATM) is greatly known for its role as an apical activator of the DNA damage response in the face of DNA double-strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA). It further plays a role in replication-dependent histone mRNA degradation.

Ataxia-telangiectasia is a rare genetic disorder that affects the nervous system, immune system and other body systems. This disorder is characterized by progressive difficulty with coordinating movements (ataxia) beginning in early childhood, usually before age 5. The research further studies that mutations in the ATM gene cause ataxia-telangiectasia. The ATM gene provides instructions for making a protein that helps control cell division and is involved in DNA repair. Therefore, this protein plays an important role in the normal development and activity of several body systems, including the nervous system and immune system.

Furthermore, this pipeline study covers products from therapy areas including Oncology, Ophthalmology and Toxicology which include indications such as Colon Cancer, Adenocarcinoma, Breast Cancer, Colorectal Cancer, Gastric Cancer, Herpetic Keratitis, Metastatic Cancer, Head And Neck Cancer, Multiple Myeloma (Kahler Disease) and Radiation Toxicity (Radiation Sickness and Acute Radiation Syndrome). In the next part, the study features detailed drug profiles for the pipeline products which includes product description, R&D brief, licensing and collaboration details, descriptive MoA and other developmental activities. The drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

The pipeline guide also reviews key companies involved in therapeutics developments of Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC and enlists all their major and minor projects. Leading companies mentioned in the report are InteRNA Technologies BV, AstraZeneca Plc and Shuttle Pharmaceuticals LLC.

Click here to get more info with TOC in a PDF Format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top